Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | DDX3X | O00571 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449437 | 0.90 | MTOR (0.60) | MTORMEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL1163657 | 0.87 | MEN1 (0.56) | MTORMEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL23763480 | 0.85 | MEN1 (0.66) | MTORMEN1KMT2APDE10ANPC1 | |
| SCHEMBL30822918 | 0.85 | DYRK1A (0.68) | MTORDYRK1ADYRK1BPDE10ACSNK1D | |
| SCHEMBL1998475 | 0.84 | AKR1C3 (0.59) | MTORMEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL1996591 | 0.83 | MEN1 (0.71) | MTORMEN1KMT2ADYRK1APDE10A | |
| SCHEMBL239690 | 0.82 | MEN1 (0.75) | MEN1KMT2APDE10ANPC1RAB9A | |
| SCHEMBL30020996 | 0.82 | MEN1 (0.75) | MEN1KMT2APDE10ANPC1RAB9A | |
| SCHEMBL2004629 | 0.82 | MEN1 (0.51) | MTORMEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL2005189 | 0.81 | MTOR (0.64) | MTORMEN1KMT2APDE10ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | claimed |
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | NOVARTIS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| CN-109641947-B | CD229CAR T cells and methods of use thereof | 犹他大学研究基金会 | 2023-04-14 | — | — | CN | disclosed |
| CN-106459989-B | Human mesothelin chimeric antigen receptor and uses thereof | 诺华股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20230013364-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | BIOATLA, LLC | 2023-01-19 | — | — | US | disclosed |
| CN-114958764-A | CD20 therapy, CD22 therapy, and combination therapy with CD19 Chimeric Antigen Receptor (CAR) -expressing cells | 诺华股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-108780084-B | Biomarkers predictive of cytokine release syndrome | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114621969-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114107424-A | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | 诺华股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-2791101-A1 | TREATMENT OF INFLAMMATION | Vascular Biogenics Ltd. (IL) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088245-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | WO | disclosed |
| US-7960561-B2 | 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2011-06-14 | — | — | US | disclosed |
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | LY96, CD74, EWSR1 | MTOR 4781/4885MEN1 3720/4885KMT2A 2155/4885 |
| US-20230013364-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | CD274, PDCD1, PDCD1LG2 | MTOR 1561/4885MEN1 1303/4885KMT2A 1476/4885 |
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | KCNN2, KCNN1, KCNN3 | MTOR 1082/4885MEN1 2186/4885KMT2A 1406/4885 |
| US-12473273-B2 | Quinoline compounds and compositions for inhibiting EZH2 | EZH2, BMI1, SUZ12 | MTOR 572/4885MEN1 2117/4885KMT2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.